197 related articles for article (PubMed ID: 36922936)
1. ZL-1211 Exhibits Robust Antitumor Activity by Enhancing ADCC and Activating NK Cell-mediated Inflammation in CLDN18.2-High and -Low Expressing Gastric Cancer Models.
Konno H; Lin T; Wu R; Dai X; Li S; Wang G; Chen M; Li W; Wang L; Sun BC; Luo Z; Huang T; Chen Y; Zhang J; Ye Q; Bellovin D; Wan B; Kang L; Szeto C; Hsu K; Kabbarah O
Cancer Res Commun; 2022 Sep; 2(9):937-950. PubMed ID: 36922936
[TBL] [Abstract][Full Text] [Related]
2. CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation.
Gao J; Wang Z; Jiang W; Zhang Y; Meng Z; Niu Y; Sheng Z; Chen C; Liu X; Chen X; Liu C; Jia K; Zhang C; Liao H; Jung J; Sung E; Chung H; Zhang JZ; Zhu AX; Shen L
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37364935
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines.
Park JE; Kim SE; Keam B; Park HR; Kim S; Kim M; Kim TM; Doh J; Kim DW; Heo DS
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32830112
[TBL] [Abstract][Full Text] [Related]
4. A bispecific antibody targeting HER2 and CLDN18.2 eliminates gastric cancer cells expressing dual antigens by enhancing the immune effector function.
Yue J; Shao S; Zhou J; Luo W; Xu Y; Zhang Q; Jiang J; Zhu MM
Invest New Drugs; 2024 Feb; 42(1):106-115. PubMed ID: 38198061
[TBL] [Abstract][Full Text] [Related]
5. Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer.
Jiang H; Shi Z; Wang P; Wang C; Yang L; Du G; Zhang H; Shi B; Jia J; Li Q; Wang H; Li Z
J Natl Cancer Inst; 2019 Apr; 111(4):409-418. PubMed ID: 30203099
[TBL] [Abstract][Full Text] [Related]
6. Development of a Humanized VHH Based Recombinant Antibody Targeting Claudin 18.2 Positive Cancers.
Zhong W; Lu Y; Ma Z; He Y; Ding Y; Yao G; Zhou Z; Dong J; Fang Y; Jiang W; Wang W; Huang Y
Front Immunol; 2022; 13():885424. PubMed ID: 35837391
[TBL] [Abstract][Full Text] [Related]
7. A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer.
Desroys du Roure P; Lajoie L; Mallavialle A; Alcaraz LB; Mansouri H; Fenou L; Garambois V; Rubio L; David T; Coenon L; Boissière-Michot F; Chateau MC; Ngo G; Jarlier M; Villalba M; Martineau P; Laurent-Matha V; Roger P; Guiu S; Chardès T; Gros L; Liaudet-Coopman E
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38290768
[TBL] [Abstract][Full Text] [Related]
8. Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody-Drug Conjugate for Treatment of CLDN18.2-Positive Cancers.
O'Brien NA; McDermott MSJ; Zhang J; Gong KW; Lu M; Hoffstrom B; Luo T; Ayala R; Chau K; Liang M; Madrid AM; Donahue TR; Glaspy JA; Presta L; Slamon DJ
Mol Cancer Ther; 2023 Dec; 22(12):1365-1375. PubMed ID: 37788341
[TBL] [Abstract][Full Text] [Related]
9. Canine non-B, non-T NK lymphocytes have a potential antibody-dependent cellular cytotoxicity function against antibody-coated tumor cells.
Kim Y; Lee SH; Kim CJ; Lee JJ; Yu D; Ahn S; Shin DJ; Kim SK
BMC Vet Res; 2019 Oct; 15(1):339. PubMed ID: 31610784
[TBL] [Abstract][Full Text] [Related]
10. Engineering of CD34+ progenitor-derived natural killer cells with higher-affinity CD16a for enhanced antibody-dependent cellular cytotoxicity.
van Hauten PMM; Hooijmaijers L; Vidal-Manrique M; van der Waart AB; Hobo W; Wu J; Blijlevens NMA; Jansen JH; Walcheck B; Schaap NPM; de Jonge PKJD; Dolstra H
Cytotherapy; 2024 Mar; 26(3):252-260. PubMed ID: 38127030
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-2 potentiation of cetuximab antitumor activity for epidermal growth factor receptor-overexpressing gastric cancer xenografts through antibody-dependent cellular cytotoxicity.
Hara M; Nakanishi H; Tsujimura K; Matsui M; Yatabe Y; Manabe T; Tatematsu M
Cancer Sci; 2008 Jul; 99(7):1471-8. PubMed ID: 18422755
[TBL] [Abstract][Full Text] [Related]
12. [
Zeng Z; Li L; Tao J; Liu J; Li H; Qian X; Yang Z; Zhu H
Eur J Nucl Med Mol Imaging; 2024 Apr; 51(5):1221-1232. PubMed ID: 38062170
[TBL] [Abstract][Full Text] [Related]
13. Characterization of zolbetuximab in pancreatic cancer models.
Türeci Ӧ; Mitnacht-Kraus R; Wöll S; Yamada T; Sahin U
Oncoimmunology; 2019; 8(1):e1523096. PubMed ID: 30546962
[TBL] [Abstract][Full Text] [Related]
14. Generation and preclinical characterization of an NKp80-Fc fusion protein for redirected cytolysis of natural killer (NK) cells against leukemia.
Deng G; Zheng X; Zhou J; Wei H; Tian Z; Sun R
J Biol Chem; 2015 Sep; 290(37):22474-84. PubMed ID: 26198633
[TBL] [Abstract][Full Text] [Related]
15. Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.
Luedke E; Jaime-Ramirez AC; Bhave N; Roda J; Choudhary MM; Kumar B; Teknos TN; Carson WE
Surgery; 2012 Sep; 152(3):431-40. PubMed ID: 22770960
[TBL] [Abstract][Full Text] [Related]
16. Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer.
Kono K; Takahashi A; Ichihara F; Sugai H; Fujii H; Matsumoto Y
Cancer Res; 2002 Oct; 62(20):5813-7. PubMed ID: 12384543
[TBL] [Abstract][Full Text] [Related]
17. Dual functional monoclonal antibody PF-04605412 targets integrin alpha5beta1 and elicits potent antibody-dependent cellular cytotoxicity.
Li G; Zhang L; Chen E; Wang J; Jiang X; Chen JH; Wickman G; Amundson K; Bergqvist S; Zobel J; Buckman D; Baxi SM; Bender SL; Casperson GF; Hu-Lowe DD
Cancer Res; 2010 Dec; 70(24):10243-54. PubMed ID: 21159645
[TBL] [Abstract][Full Text] [Related]
18. A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximab.
Fujii R; Schlom J; Hodge JW
J Neurosurg; 2018 May; 128(5):1419-1427. PubMed ID: 28753113
[TBL] [Abstract][Full Text] [Related]
19. Pluripotent stem cell-derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity.
Zhu H; Blum RH; Bjordahl R; Gaidarova S; Rogers P; Lee TT; Abujarour R; Bonello GB; Wu J; Tsai PF; Miller JS; Walcheck B; Valamehr B; Kaufman DS
Blood; 2020 Feb; 135(6):399-410. PubMed ID: 31856277
[TBL] [Abstract][Full Text] [Related]
20. Leveraging CD16 fusion receptors to remodel the immune response for enhancing anti-tumor immunotherapy in iPSC-derived NK cells.
Meng F; Zhang S; Xie J; Zhou Y; Wu Q; Lu B; Zhou S; Zhao X; Li Y
J Hematol Oncol; 2023 Jun; 16(1):62. PubMed ID: 37316891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]